Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Study of Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Subjects with Hodgkin Lymphoma
Sponsor:National Cancer Institute NCI NIH DHHS
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS7604
U.S. Government ID:NCT01896999
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to compare the combination of brentuximab vedotin and nivolumab to the combination of brentuximab vedotin, nivolumab, and ipilimumab. Both brentuximab vedotin and nivolumab are FDA-approved as single drugs for patients who have relapsed or refractory Hodgkins lymphoma. The combination of these drugs together, and with ipilimumab are not FDA-approved, so this therapy is considered an experimental treatment. The addition of ipilimumab to brentuximab vedotin and nivolumab may or may not shrink your cancer and keep it away for longer than the combination of brentuximab and nivolumab. It may also cause more side effects.This study will help the study doctors find out if this combination approach is the same or better than the usual approach of using these drugs alone. To decide if it is better, the study doctors will be looking to see if the study drugs shrink patients cancer using both treatments, and which combination shrinks Hodgkin lymphoma better with reasonable side effects. There will be about 120 people taking part in this study.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have relapsed or refractory classical Hodgkin Lymphoma (cHL)?YesNo
Have you been treated with at least one previous therapy (ie. chemotherapy, autologous or allogeneic stem cell transplant, etc)?YesNo
Submit
Cancel
Investigator
Jennifer Amengual, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162